470
Participants
Start Date
September 8, 2017
Primary Completion Date
March 26, 2020
Study Completion Date
March 26, 2020
D-SUIV cH8/1N1+AS03
1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 03 (AS03) was administered intramuscularly (IM) in the deltoid region of non-dominant arm.
D-SUIV cH5/1N1+AS03
1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
D-SUIV cH11/1N1+AS03
1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
D-SUIV cH8/1N1+AS01
1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
D-SUIV cH5/1N1+AS01
1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
D-SUIV cH11/1N1+AS01
1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
D-SUIV cH8/1N1
1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
D-SUIV cH5/1N1
1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
D-SUIV cH11/1N1
1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
Placebo
1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
Fluarix Quadrivalent
1 Primary dose and 1 Booster dose was administered IM in the deltoid region of non-dominant arm.
GSK Investigational Site, Wilrijk
GSK Investigational Site, Rochester
GSK Investigational Site, Norfolk
GSK Investigational Site, South Miami
GSK Investigational Site, Wichita
GSK Investigational Site, Austin
Lead Sponsor
GlaxoSmithKline
INDUSTRY